Could molecular variations be predictive in right and left colon cancer in different gender and age groups?
Summary
This in-silico study investigated gene expression differences between right-sided (RCC) and left-sided colon cancer (LCC) using the TCGA-COAD database to clarify their distinct molecular and clinical features. Researchers identified age and gender-related genes, including TG, INSL5, EREG, AIRE, HOXB8, and FLT3. High expression of AIRE and LEP, and low expression of EREG, were correlated with poorer survival in specific RCC patient subgroups. These three genes, which are involved in the EGFR pathway, are proposed to hold significant predictive and prognostic value for anti-EGFR therapies.
Analysis
🔴 CLINIQUE: This in-silico study, based on TCGA data, suggests that AIRE, LEP, and EREG genes could hold predictive and prognostic value for anti-EGFR therapies, particularly in RCC patients. For instance, high AIRE expression is linked to poorer survival in male RCC patients under 65, and low EREG expression in female RCC patients. While preliminary and requiring prospective validation, these findings could justify further clinical trials to evaluate these biomarkers and potentially refine patient selection for anti-EGFR treatments. Clinical impact could be seen in 3-5 years if these biomarkers are validated. 🟢 BIOMOL: The discovery of differentially expressed genes such as TG, INSL5, EREG, AIRE, HOXB8, and FLT3, linked to age and gender, sheds light on new avenues for understanding colorectal cancer heterogeneity. mRNA expression analysis from the TCGA-COAD database identified AIRE, LEP, and EREG, in particular, as being involved in the EGFR signaling pathway. These genes could serve as novel predictive or prognostic biomarkers, paving the way for clinical tests to guide targeted therapies. 🔵 BIOINFO: The study employed a bioinformatics approach to analyze mRNA expression levels from the public TCGA-COAD database (216 RCC, 141 LCC). The methodology included identifying differentially expressed genes, analyzing survival profiles, and performing gene set enrichment analysis. This in-silico approach represents an incremental application of established methods for genomic data exploration. The results are based on a large public dataset, which is a strength for reproducibility, but require experimental and clinical validation to confirm their relevance.